LATEST NEWS
  •  
    Self-styled '156-year-old startup' aims to attract small-to-medium companies with outsourced commercialization services
    Dohmen Life Science Services (DLSS; Milwaukee) took the wraps off a newly structured organization which, says CEO Cynthia LaConte, "is a rethinking of our business, based on a future of entrepreneurially driven pharma companies with high-value, small-market products." At a company-sponsored "Entrepreneurial Summit" held this week in Milwaukee, LaConte outlined the recent history of the firm, going back to when it shed its 100+-year-old wholesaling business, then acquired, in rapid succession in the past several years, businesses that are involved in orphan-drug patient support; medical device distribution; clinical research support, post-marketing support and several other specialties. Along the way, it built out its DDN
  •  
    The pervasiveness of e-prescribing allows for better analysis of adherence, says NEHI
    An issue brief just published by the Network for Excellence in Health Innovation (NEHI; Boston) highlights both the continuing problem of medication adherence, and how a changing healthcare system--specifically, the prevalence of e-prescribing--provides deeper detail on the problem. It also raises the possibility that, with the appropriate incentives in place, community pharmacy could become a more effective means of addressing non-adherence. As has long been known, patients' adherence to prescribed therapies is poor,
  •  
    HDMA's research arm studies biosimilar market dynamics
    Biosimilars market dynamics are already taking shape in Europe, but the contrast between pharmacy benefits and medical benefits, and the effects of commercial insurers, will create a different set of dynamics when more biosimilars enter the US market. That's a preliminary view from the Center for Healthcare Supply Chain Research, the research arm of HDMA, in a newly issued report, "Biosimilars: Lessons from Europe and Strategies for the US." Some background: biosimilars are the biologic compounds meant to replicate the therapeutic action of commercialized biologics,
  •  
    Cardinal Health works with Americares, and McKesson with World Vision, to deliver supplies
    One million product items, including masks, gowns, biohazard bags and shoe covers have been provided by Cardinal Health for use in Liberia and Sierra Leone, where current estimates are that as many as 1.4 million residents in the two countries might ultimately be affected. The donation, being handled in multiple shipments, is managed by Americares, Inc. (Stamford CT), which works with many US healthcare products manufacturers to provide emergency relief in the developing world following natural disasters and epidemics like the current Ebola crisis. "As a company with concerns for the health and well-being of people
  •  
    Company is part of limited distribution for a Lundbeck neurologic treatment
    Business is looking good at Omnicare Specialty Care Group (SCG), a business unit of the Cincinnati company best known for its pharmaceutical services for long-term, assisted-living and other types of chronic care. SCG has opened a new, 75,000-sq.ft. facility in Louisville, KY, for its RxCrossroads unit, dedicated to brand support for specialty pharmaceuticals--more than doubling the RxCrossroads capacity. The building will house RxCrossroads management, HR, IT functionsas well as employee training. "This expansion comes as a result of the double-digit growth in the Specialty Care Group (SCG) segment, and better positions RxCrossroads to fulfill the evolving long-term needs of our customers," said Amit Jain
  •  
    Payer trends dominate near-term outlook
    The IMS Health Institute for Healthcare Informatics has published a white paper, "Harbingers of Change in Healthcare: Implications for the role and use of medicines," that's worth a look. It is a little sketchy on how the 10 items were chosen (the report lists five IMS Health analysts as authors; and that's it), while noting that the list is "not intended to be exhaustive." On the other hand, the items are backed up by up-to-date market data (IMS Health's core service); for example, it notes that Medicare prescriptions for sofosburvir (Gilead Science's Sovaldi) and simeprivir (J&J's Olysio), for hepatitis C, jumped eightfold (to over 105,000 prescriptions
  •  
    New study suspects Indian manufacturers 'differentiate drug quality according to the destination of consumption'
    A messy situation is getting messier for Indian manufacturers, in particular those producing generics for export. On Sept. 22, FDA added more drugs from Apotex' Bangalore, India, facility to ongoing "detention without physical examination" restrictions; in effect, these Apotex drugs are banned from importation. That action motivated Health Canada to do more or less the same, even though it had given Apotex an all-clear in an inspection earlier this year. "Health Canada last inspected the [Bangalore] facility in February 2014 with an international regulatory partner. The visit resulted in a compliant rating. The FDA had issued a compliant rating
  •  
    DHL garners headlines with a 'parcelcopter' delivering daily drugs to remote North Sea island
    DHL Parcel (Bonn, Germany) has joined in the buzz generated by Amazon, and the entire unmanned aircraft movement, with a pilot (folks in this field will have to stop using that word!) program to deliver prescribed drugs to a pharmacy in Juist, an island in the North Sea. The device, flying at 18 meters/s, will make a run from the harbor in Norddeich to Juist, carrying a customized air-transport container. DHL Parcel straddles the "autonomous" aspect of this project; while insisting that the device is unpiloted, it will also have continuous monitoring from a station at Norddeich. Once the project "takes off" (DHL's phrase), vacationers and island residents can receive prescriptions several times a week, particularly "on times when such alternatives as ferries and flights are not available"
  •  
    Regulatory compliance continues to exceed cost as a primary driver
    UPS' seventh global survey of supply chain managers in healthcare products finds a greater consensus of industry goals regarding supply chain management, but a lesser degree of actually following through on those goals. All this is occurring in a context of rapid change, driven by the desire to tap into global markets, adoption of new distribution channels, and the urgency to keep up with expanding regulatory compliance initiatives. "One of the values of this survey is the timeline it establishes for industry issues," notes John Menna, VP for healthcare strategy. "In past years, we've asked about global initiatives and found that 81% of healthcare executives planned
  •  
    Vendor-managed system inventories and protects specialty pharmaceuticals in healthcare settings
    The ASD Healthcare unit of AmerisourceBergen (Frisco, TX) is a specialty distributor of oncology, nephrology and blood-derivative products for specialty pharmacies and clinics; for the past several years it has marketed a combined storage and inventory-management system called Cubixx. The Cubixx unit (see photo) is a refrigerator-sized, powered unit that employs RFID technology to track inventory, record additions and removals and provide security for the high-value products typically stored within it. Keeping the inventory under temperature-controlled (cold chain) conditions is also an important feature
  •  
    Pharmaceutical Commerce's latest report finds continued growth in these specialized logistics services
    The 5th edition of the Biopharma Cold Chain Sourcebook analyzes economic, regulatory and technological trends in a vital part of today's industry: the shipment of temperature-controlled products. The just-published report calculates that current (2014) expenditures for commercial shipments will be $8.36 billion, rising to $10.28 billion in 2018. By comparison, last year's Sourcebook estimated the 2013 cold-chain business to be $7.5 billion, rising
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the September/October 2014 Issue now - It's Free!
COLD CHAIN FOCUS
Tracking systems dominate product introductions
 
INDUSTRY EVENTS
 
 
 
 
WHAT THEY'RE SAYING
Pharmaceutical Commerce sat down with Mr. Mortazavi recently; here's what he had to say
 
 
FEATURES
The drive for lower costs, safer products  continued >
 
True 'market access' should involve coordinated approaches to patients and their healthcare providers  continued >
 
MDM practices are moving far beyond compliance concerns  continued >
 
The eye-popping price tag on the hepatitis C drug, from Gilead Sciences, has prompted unprecedented pushback from payers  continued >
 
 
MOST POPULAR STORIES
 
 
SPECIAL FOCUS REPORT
2014 Cold Chain Directory
 
Our annual compilation of key vendors and service providers in this vital component of pharmaceutical distribution, together with a preview of the IQPC Cold Chain Forum and more late-breaking news
 
CLINICAL OPERATIONS
TrialRx service analyzes and mitigates disclosure risks
 
 
 
   
  |     |     |     |     |     |  
©2014 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.